Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments.
Abiologics develops biologic drugs from building blocks not used by nature, which it says confers these proteins with properties that make for better medicines. Founded by Flagship Pioneering, the startup is focusing on developing novel biologic treatments for cancer and immunology.
Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized. With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business.
Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Pfizer and Flagship Pioneering are partnering in a drug research alliance leveraging the capabilities of the more than 40 biotech startups in the venture capital firm’s portfolio. The new partners aim to develop drugs for unmet needs, including those in broad patient populations.
Scientists at Empress Therapeutics say molecules that co-evolved with humans over millennia are a promising source of new drugs. With its AI-driven technology platform, the Flagship Pioneering-founded startup finds them.
Metaphore Biotechnologies leverages the concept of biomimicry for developing new drugs with potential applications in autoimmune diseases, metabolic disorders, and cancer. Flagship Pioneering is backing the startup with $50 million.
Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.
Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.
Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies. The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company.
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.
ProFound Therapeutics emerged from stealth with technology that it claims has discovered tens of thousands of previously undiscovered proteins—many of them promising new drug targets. The Flagship Pioneering-founded startup is backed by $75 million to support its drug R&D along with plans to partner with large pharmaceutical companies.
Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.
Kaleido Biosciences, formed by Flagship Pioneering as part of a wave of biotech companies developing microbiome therapies, has laid off its entire workforce and is winding down operations. The shutdown follows a strategic review that failed to turn up any deals to support its clinical-stage pipeline.